< Back to situations

[ORGANIZATION]

CRISPR Therapeutics

Featured in 3 tracked stories · first seen

Situations

[QUIET] [BUSINESS] [US]

FDA review of Grail Galleri cancer blood test

2 clusters · 2 sources · last updated

Latest: Biotech firms Grail and CRISPR Therapeutics see regulatory developments

The U.S. Food and Drug Administration (FDA) has scheduled an advisory committee meeting for September 23, 2026, to review the premarket approval application for Grail Inc.’s Galleri multi-cancer early detection (MCED) bl

[QUIET] [BUSINESS] [US]

Biotechnology sector market volatility

2 clusters · 5 sources · last updated

Latest: Market Update: Costco, Xencor, and various biotech firms report earnings and stock shifts

The biotechnology sector experienced notable stock price volatility and varied financial reporting in late August 2026. Initially, Recursion Pharmaceuticals and CRISPR Therapeutics saw significant share price gains, wit

Also covered in